Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
Clinical Snapshot
Lower urinary tract symptoms (LUTS) in men are voiding, storage, and postmicturition symptoms that commonly arise from benign prostatic hyperplasia (BPH) — a nonmalignant, androgen-dependent proliferation of prostatic epithelial and stromal tissue that begins in the periurethral transition zone and can progress to bladder outlet obstruction. Two mechanisms coexist and most pharmacotherapy targets one or the other: a static component (the physical bulk of an enlarged gland narrowing the urethral lumen) and a dynamic component (alpha1-adrenergic-receptor-mediated smooth-muscle tone in the bladder neck, prostate, and urethra). LUTS is common, but LUTS is not synonymous with BPH — prostate cancer, urinary tract infection, neurogenic bladder, urethral stricture, and overactive bladder unrelated to prostatic enlargement can all produce an identical symptom picture, so ruling out other causes is part of every initial workup, not an afterthought. The goals of therapy are to improve or resolve bothersome symptoms, delay or prevent clinical progression, and prevent the long-term sequelae of unrelieved bladder outlet obstruction — recurrent urinary tract infection, bladder stones, and obstructive uropathy with renal impairment.[1] Current Canadian practice follows the 2022 Canadian Urological Association (CUA) guideline update, cross-checked against the 2023 American Urological Association (AUA) guideline amendment and the 2026 European Association of Urology (EAU) guideline on non-neurogenic male LUTS.[2][3]
Recognize the Condition
LUTS are conventionally grouped into 3 domains; most patients have a mixture, but identifying which domain predominates directly shapes drug selection.
The 3 LUTS symptom domains
Voiding (obstructive) symptoms
Weak or interrupted urinary stream, hesitancy, straining to void, and a sensation of incomplete bladder emptying. Reflects bladder outlet obstruction from the static and/or dynamic components of prostatic enlargement.
Storage (irritative) symptoms
Urinary frequency, urgency, urgency incontinence, and nocturia. These can reflect secondary detrusor overactivity, or, separately, nocturnal polyuria — the two need to be distinguished, since they are managed differently.
Postmicturition symptoms
Post-void dribbling and a persistent sensation of incomplete emptying immediately after voiding.
Onset is typically gradual over years and severity fluctuates over time. A sudden, severe change — especially complete inability to void — is not typical of gradually progressive BPH and should prompt evaluation for acute urinary retention or an alternative cause rather than being assumed to be a BPH flare.
Risk Factors
- Increasing age — the single strongest risk factor; BPH is uncommon before age 40 and becomes progressively more common with each subsequent decade.
- Family history of BPH, particularly in a first-degree relative.
- Intact testicular androgen production — BPH does not develop in men castrated before puberty, underscoring the androgen dependence of the condition.
- Obesity and features of metabolic syndrome.
- Possibly type 2 diabetes and reduced physical activity, though the evidence for these is less consistent than for the factors above.
Red Flags & Refer
Exclude every item below before treating LUTS as presumptive, uncomplicated BPH:
- Acute urinary retention — complete inability to void with a painful, palpable/percussible bladder — requires immediate catheterization; this is an emergency, not something to trial oral medication for first.
- Gross hematuria — visible blood in the urine requires assessment to exclude bladder or upper-tract pathology before it is attributed to prostatic hypervascularity.
- Signs suggesting prostate cancer — an abnormal digital rectal examination (a hard, nodular, or asymmetric prostate) or a markedly elevated or rapidly rising PSA — require urology referral before presumptive BPH treatment is started.
- Signs of urosepsis or obstructive uropathy with renal impairment — fever, flank pain, or a rising creatinine in the setting of LUTS need urgent assessment, not routine BPH management.
- Recurrent urinary tract infections, bladder stones, or a new neurologic deficit (saddle anesthesia, lower-limb weakness, new bowel or bladder incontinence) suggesting an alternative or coexisting diagnosis such as neurogenic bladder.
- A history of urethral instrumentation, trauma, or a prior urethritis (e.g., gonococcal) with symptoms suggesting urethral stricture rather than prostatic obstruction.
Assessment & Diagnosis
Differentiating BPH-related LUTS from its mimics
| Feature | BPH-related LUTS | Prostate cancer | UTI / acute bacterial prostatitis | Overactive bladder unrelated to BPH | Neurogenic bladder |
|---|---|---|---|---|---|
| Onset/course | Gradual, progressive over years | Often asymptomatic; LUTS occurs late/with locally advanced disease | Acute onset, over days | Storage symptoms only, can occur at any adult age | Associated with known neurologic disease or injury |
| DRE | Smooth, firm, symmetrically enlarged, nontender | Firm/hard nodule, asymmetry, induration | Acutely tender, boggy, warm prostate — avoid a vigorous DRE if this is suspected | Normal | Variable; may have reduced anal sphincter tone |
| PSA | May be mildly elevated, proportional to gland volume | Markedly elevated or rapidly rising | Often transiently elevated — recheck after treating the acute infection, not during it | Normal | Normal |
| Key distinguishing clue | Gradual voiding ± storage symptoms with a normal urinalysis | Abnormal DRE and/or markedly elevated or rapidly rising PSA | Fever, dysuria, positive urinalysis/culture | Storage symptoms only, no voiding symptoms, normal post-void residual | Saddle anesthesia, lower-limb weakness, abnormal perineal sensation or reflexes |
| Initial differentiating test | DRE, selective PSA, symptom inventory | DRE and PSA, then urology referral for biopsy if abnormal | Urinalysis and culture | Post-void residual (normal) and voiding diary | Neurologic exam, urodynamics |
History (mandatory)
- Characterize voiding symptoms (weak/interrupted stream, dribbling, hesitancy, straining) and storage symptoms (nocturia, frequency, urgency) separately.
- Onset, progression, and degree of bother — a formal symptom inventory such as the International Prostate Symptom Score (IPSS; see below) is recommended at initial consultation, during watchful waiting, and to track treatment response.
- Details of urethral infection, instrumentation, or injury (trauma, surgery, radiation).
- Prior episodes of urinary tract infection, hematuria, or urinary retention.
- Full medication review, including over-the-counter drugs and phytotherapeutic products — diuretics, decongestants, antihistamines, and antidepressants with anticholinergic activity can all worsen LUTS.
Physical examination (mandatory)
- Abdomen — bladder distention, flank tenderness.
- External genitalia — phimosis, meatal stenosis, urethral mass or induration.
- Digital rectal examination — document prostate size, consistency, symmetry, and tenderness, and note anal tone and any rectal abnormality.
Laboratory testing
- Urinalysis (mandatory), with urine culture if bacteriuria or pyuria is found — needed to rule in/out causes other than BPH.
- PSA (recommended, selectively) — offer to patients with at least a 10-year life expectancy for whom knowledge of prostate cancer would change management, and to those for whom a PSA result would help estimate prostate volume relevant to LUTS management.[1] This is a different clinical question from population-based prostate cancer screening in an asymptomatic man, where routine PSA screening is not generally recommended — the guidance above applies specifically to the diagnostic workup of a man who already has LUTS.
Optional, when diagnostic uncertainty exists
- Serum creatinine, urine cytology, uroflowmetry, and post-void residual (PVR).
- A frequency-volume voiding diary, especially when nocturnal polyuria is suspected as the driver of bothersome nocturia.
- Obstructive sleep apnea screening (e.g., STOP-BANG questionnaire) in men over 50 with nocturia, since untreated OSA is a treatable contributor.
- A sexual function questionnaire, particularly when a PDE5 inhibitor is being considered.
Not routinely indicated
Cytology, cystoscopy, urodynamics, radiologic imaging of the upper urinary tract, prostate ultrasound, and prostate biopsy are not part of the routine initial evaluation of typical BPH-related LUTS. Reserve these for hematuria, genuine diagnostic uncertainty, an abnormal DRE, poor response to medical therapy, or surgical planning (where cystoscopy and prostate ultrasound to determine volume and median-lobe presence become appropriate).[1]
International Prostate Symptom Score (IPSS)
The IPSS is a validated, patient-completed, 7-question symptom inventory. Each question is scored 0 to 5 by the patient, and the 7 scores are summed to a total of 0 to 35.[4]
| Question (over the past month) | Not at all (0) | Less than 1 in 5 times (1) | Less than half the time (2) | About half the time (3) | More than half the time (4) | Almost always (5) |
|---|---|---|---|---|---|---|
| Incomplete emptying — sensation of not emptying the bladder completely after finishing urinating | 0 | 1 | 2 | 3 | 4 | 5 |
| Frequency — needing to urinate again less than 2 hours after finishing | 0 | 1 | 2 | 3 | 4 | 5 |
| Intermittency — stopping and starting again several times while urinating | 0 | 1 | 2 | 3 | 4 | 5 |
| Urgency — finding it difficult to postpone urination | 0 | 1 | 2 | 3 | 4 | 5 |
| Weak stream | 0 | 1 | 2 | 3 | 4 | 5 |
| Straining — having to push or strain to begin urination | 0 | 1 | 2 | 3 | 4 | 5 |
| Nocturia — number of times getting up to urinate from bedtime to waking (scored None=0, 1 time=1, 2 times=2, 3 times=3, 4 times=4, 5 or more times=5) | 0 | 1 | 2 | 3 | 4 | 5 |
Total score interpretation: 0-7 = mildly symptomatic; 8-19 = moderately symptomatic; 20-35 = severely symptomatic.[4] An additional, separately scored quality-of-life/bother question (0 = delighted to 6 = terrible) accompanies the 7-item index in the full instrument; it is not part of the 0-35 sum but is clinically important, since treatment decisions should follow the degree of bother at least as much as the numeric score. The IPSS is a symptom-severity index, not a diagnostic test — it does not distinguish BPH from other causes of LUTS and does not correlate closely with objective measures such as prostate volume or peak flow rate, so use it to grade severity and track response to treatment, not to confirm the diagnosis.
Treatment Targets
- Improve or resolve bothersome voiding, storage, and postmicturition symptoms.
- Delay or prevent clinical progression of BPH — worsening symptoms, acute urinary retention, or the eventual need for BPH-related surgery.
- Prevent the long-term sequelae of unrelieved bladder outlet obstruction: recurrent urinary tract infection, bladder stones, and obstructive uropathy with renal impairment.
- Preserve sexual function where possible, and weigh the patient's own tolerance for sexual side effects against symptom control when selecting a drug.
- Align the treatment plan with the patient's own therapeutic goal through shared decision-making, and document that goal.[1]
Choose Initial Treatment
Manage men with mild symptoms (IPSS under 8) and no bother with reassurance, lifestyle modification, and active surveillance rather than starting a drug.
Start pharmacotherapy in men with bothersome moderate-to-severe symptoms (IPSS 8-35), or bother at any severity, once red flags have been excluded.
1st line for voiding-predominant symptoms, any gland size — alpha1-adrenergic receptor antagonist (alpha-blocker) monotherapy: tamsulosin 0.4 mg PO once daily (may increase to 0.8 mg once daily if well tolerated but response is insufficient), alfuzosin 10 mg PO once daily after the same meal each day, or silodosin 8 mg PO once daily after the same meal (4 mg once daily if creatinine clearance is 30-50 mL/min; avoid below that). Doxazosin and terazosin (1-8 mg and 1-10 mg PO once daily at bedtime respectively) are nonuroselective alternatives that require dose titration and blood pressure monitoring. All 5 agents have equal clinical effectiveness for LUTS — choice depends on side-effect profile, comorbidities, and cost. Tamsulosin, the most uroselective and most widely used agent, is also the alpha-blocker most consistently linked to intraoperative floppy iris syndrome during cataract surgery — ask about current or prior alpha-blocker use before any planned cataract surgery (see Special Populations).[1]
Add a 5-alpha-reductase inhibitor for demonstrable prostatic enlargement (over 30 cc) and/or a higher PSA — finasteride 5 mg PO once daily or dutasteride 0.5 mg PO once daily. 5-alpha-reductase inhibitors reduce prostate volume gradually and take up to 6-12 months for their full effect on symptoms and progression risk — do not expect or promise rapid relief. Efficacy is best demonstrated in men with a prostate volume over 30 cc and/or a PSA over 1.5 ng/mL; a 5-ARI is generally not useful monotherapy in a man with a small gland and low PSA.[1]
Combination therapy — alpha-blocker plus 5-ARI — for bothersome LUTS with demonstrable prostatic enlargement (over 30 cc), combine an alpha-blocker with a 5-alpha-reductase inhibitor from the outset rather than sequencing them; the fixed-dose dutasteride/tamsulosin combination (Jalyn) is a convenient single-capsule option. Once a patient has been successfully managed on combination therapy for 6-9 months, it is reasonable to offer discontinuing the alpha-blocker component and continuing the 5-ARI alone; restart the alpha-blocker if symptoms recur.[1]
Coexisting erectile dysfunction — tadalafil 5 mg PO once daily, the only PDE5 inhibitor approved for daily LUTS management, is a reasonable monotherapy or add-on for men with both LUTS and erectile dysfunction.[1] Do not add tadalafil to an alpha-blocker without first stabilizing the patient on the alpha-blocker — the combination can cause clinically significant hypotension, and tadalafil is absolutely contraindicated with any nitrate or a guanylate cyclase stimulator (e.g., riociguat).
Storage-predominant or mixed symptoms with persistent bother — an antimuscarinic (fesoterodine, oxybutynin, solifenacin, or tolterodine) or the beta-3 agonist mirabegron, alone or added to an alpha-blocker, is appropriate for bothersome storage symptoms; current EAU guidance has strengthened the evidence rating specifically for beta-3 agonist therapy in this setting.[3] Use these agents with caution, or avoid, in men with a post-void residual over 200-300 mL or a history of spontaneous acute urinary retention — they carry a real, if small, urinary retention risk that is highest in the first month of treatment.[1]
Bothersome nocturia confirmed as nocturnal polyuria on a voiding diary, not responding to conservative measures or other BPH therapy — desmopressin, at the lowest effective dose, with baseline and scheduled serum sodium monitoring (see Monitoring and Follow-up).[1]
Acute urinary retention — immediate catheterization is mandatory; starting an alpha-blocker (tamsulosin, alfuzosin, or silodosin specifically) during the catheterization period increases the chance of successfully voiding once the catheter is removed, and adding a 5-alpha-reductase inhibitor may reduce the risk of needing BPH surgery in the future.[1]
Non-Pharmacologic Treatment
Lifestyle and behavioural measures
- Manage men with mild, non-bothersome symptoms with reassurance and active surveillance — periodic reassessment — rather than starting a drug.
- Restrict fluid intake in the hours before bedtime, particularly for men whose main complaint is nocturia.
- Reduce or avoid caffeinated beverages, alcohol, and spicy foods.
- Review medications that can worsen LUTS and adjust or avoid them where possible: diuretics, decongestants and other alpha-adrenergic agonists, antihistamines, and antidepressants with anticholinergic activity.
- Try timed or organized voiding (bladder retraining) for bothersome storage symptoms.
- Identify and treat constipation, which can worsen bladder outlet symptoms.
- Encourage weight loss and management of metabolic syndrome where present.
- Refer for pelvic floor physical therapy when a non-relaxing pelvic floor is suspected as a contributor to LUTS, pelvic/genital pain, or bowel/sexual dysfunction.
- Advise men with pedal edema to elevate their legs before bedtime to reduce nocturnal fluid redistribution and resulting nocturia.
- Use a shared decision-making aid to walk through treatment options and document the patient's own therapeutic goal.[1]
Procedures
Surgical intervention is appropriate for men with an absolute indication — recurrent or refractory urinary retention, recurrent urinary tract infection, bladder stones, recurrent gross hematuria from prostatic hypervascularity, or renal insufficiency secondary to bladder outlet obstruction — or for men with symptom deterioration despite medical therapy, or a preference to stop medical therapy for a more definitive treatment. Modality selection depends on prostate volume, presence of a median lobe, fitness for anesthesia, anticoagulant/antiplatelet therapy, and how much the patient values preserving ejaculatory function; local urologist consultation determines what is actually available.[1] The field continues to shift toward tissue- and ejaculation-preserving techniques as evidence for newer technologies matures.[2][3]
Surgical approach by prostate volume
Under 30 cc, no median lobe
Transurethral incision of the prostate, or transurethral resection.
30-80 cc
Transurethral resection (monopolar or bipolar), laser/plasma enucleation, or photoselective vaporization — the current standard options for this size range.
Over 80 cc
Enucleation, open or robotic simple prostatectomy, or vaporization, depending on local expertise.
Unfit for anesthesia, or ejaculation preservation prioritized
Prostatic urethral lift, convective water vapor thermal therapy, or robotic waterjet ablation may be reasonable alternatives depending on gland size, median lobe presence, and local availability.
| Procedure | Best-suited scenario | Adverse effect profile | Comments |
|---|---|---|---|
| Transurethral incision of the prostate (TUIP) | Small gland, no median lobe | Lower risk of retrograde ejaculation than resection | Higher rate of needing a repeat procedure than resection. |
| Transurethral resection of the prostate (monopolar or bipolar TURP) | Moderate gland (30-80 cc) | Retrograde ejaculation is common; bleeding, urethral stricture, and bladder neck contracture can occur | The long-standing reference standard for efficacy; bipolar technique lowers perioperative bleeding risk compared with monopolar. |
| Photoselective vaporization (e.g., GreenLight laser) | Moderate gland, or men on anticoagulant/antiplatelet therapy | Similar overall complication profile to TURP with less bleeding | Comparable durable symptom improvement to TURP. |
| Anatomic endoscopic enucleation (e.g., holmium, thulium, or GreenLight laser enucleation) | Any gland size over 30 cc | Retrograde ejaculation is common; overall safety profile favourable, including in men on anticoagulants | Removes more adenoma tissue than resection; a steep learning curve for the surgeon. |
| Open or robotic-assisted simple prostatectomy | Very large glands, or concurrent bladder pathology (large stones, diverticulum) | The most invasive option; longer hospitalization and catheterization; transient urinary incontinence and urethral stricture can occur | Reserved for glands too large for endoscopic enucleation where that expertise is unavailable. |
| Convective water vapor thermal therapy (e.g., Rezum) | Smaller-to-moderate glands, including with a median lobe, when preserving ejaculatory function is a priority | Erectile and ejaculatory function are typically preserved | Can be performed under local anesthesia in appropriately selected patients. |
| Prostatic urethral lift (e.g., UroLift) | Smaller-to-moderate glands, when preserving ejaculatory function is a priority | Ejaculatory function is typically preserved; dysuria and hematuria are common early after the procedure | Less effective than TURP for symptom reduction but avoids resection-related sexual side effects. |
| Robotic waterjet ablation (Aquablation) | A wide range of gland sizes, including larger glands, when preserving ejaculatory function is a priority | Erectile and ejaculatory function are largely preserved | Image-guided, robotically executed tissue removal. |
| Temporary implanted nitinol device (iTIND) | Smaller-to-moderate glands, when preserving ejaculatory function is a priority | Erectile and ejaculatory function are preserved | Temporary device removed after several days under local anesthetic. |
| Prostatic artery embolization | Men at high surgical/anesthesia risk, at centers with interventional radiology expertise | Fewer procedural complications than TURP, but less durable symptom control | Also considered for gross hematuria of prostatic origin. |
| Long-term indwelling catheter or clean intermittent self-catheterization | Men who are not candidates for any other intervention | Ongoing catheter-related risks (infection, encrustation) | A reasonable long-term option when surgery is not feasible or not wanted. |
Special Populations
BPH-related LUTS is a condition of the aging prostate and does not occur in pediatric patients — no pediatric dosing applies to any drug in this chapter.
Pregnancy and breastfeeding
BPH-related LUTS does not itself arise in pregnancy or lactation, since it occurs only in patients with a prostate. However, both finasteride and dutasteride carry a real teratogenic risk to a male fetus through partner exposure — a pregnant partner, or a partner who may become pregnant, should not handle crushed or broken 5-alpha-reductase inhibitor tablets, and condom use is advised during intercourse for men taking these drugs whose partner is or may become pregnant, since the drug is present in semen. Intact tablets can be handled normally by anyone.
Renal impairment
Silodosin requires dose reduction (4 mg once daily) at a creatinine clearance of 30-50 mL/min and should be avoided below 30 mL/min. Desmopressin requires extra caution and closer sodium monitoring in renal impairment (see Monitoring and Follow-up). New or worsening renal impairment in a man with LUTS may itself signal advanced obstructive uropathy and warrants more urgent workup and consideration of urology referral rather than routine BPH management.
Hepatic impairment
Avoid alfuzosin and silodosin in significant hepatic impairment. Tadalafil is not recommended in severe hepatic impairment. Use 5-alpha-reductase inhibitors with caution in significant liver disease.
Older adults
Nonuroselective alpha-blockers (doxazosin, terazosin) carry a meaningfully higher orthostatic hypotension and fall risk in older men — favour a uroselective agent, or dose at bedtime, where an alpha-blocker is indicated. Antimuscarinics carry cumulative anticholinergic burden that can worsen cognition and falls risk in frail older men — favour mirabegron, fesoterodine, or tolterodine over oxybutynin when an agent with lower central nervous system penetration is preferred. Desmopressin's hyponatremia risk rises substantially with age — monitor more closely in men 65 and older.
Cardiovascular disease and heart failure
An observational Canadian study found an association between alpha-blocker and/or 5-alpha-reductase inhibitor exposure and new heart failure in men over 66 years of age, with the strongest signal for nonselective alpha-blockers used alone.[5] Weigh the benefit of symptom relief against this signal in men with existing heart failure or significant cardiovascular disease, favour a uroselective alpha-blocker where an alpha-blocker is still indicated, and monitor for new or worsening heart failure symptoms after starting therapy in this population.
Intraoperative floppy iris syndrome and cataract surgery
Alpha1-blockers — tamsulosin most consistently — are associated with intraoperative floppy iris syndrome (IFIS), a combination of iris billowing, progressive intraoperative miosis, and iris prolapse toward the surgical incision during cataract surgery.[6] Ask every patient about current or prior alpha-blocker use before any planned cataract surgery, including men who stopped the drug months to years earlier, since the association can persist after discontinuation. This should be disclosed to the operating ophthalmologist in advance so the surgical team can plan for it, rather than discovering it intraoperatively — IFIS is manageable with advance notice and is not, on its own, a reason to withhold or stop alpha-blocker therapy for LUTS. See the Cataract Surgery Postoperative Care chapter for more detail on perioperative management.
PSA interpretation on 5-alpha-reductase inhibitor therapy
Both finasteride and dutasteride suppress serum PSA, and this must be accounted for when interpreting PSA results in a man on 5-ARI therapy. Establish a new PSA baseline at 6 months after starting a 5-alpha-reductase inhibitor and continue periodic monitoring from that new baseline. For a man who started a 5-ARI without a repeat post-treatment baseline, doubling the on-treatment PSA value provides a reasonable approximation of the untreated value when interpreting results for prostate cancer risk. Any confirmed rise in PSA from the on-treatment value while a patient remains on a 5-alpha-reductase inhibitor should prompt assessment for high-grade prostate cancer, since 5-ARI use does not eliminate prostate cancer risk.[1]
Prostate cancer risk-reduction counselling
Neither finasteride nor dutasteride is approved in Canada for prostate cancer prevention, but randomized trial evidence shows both agents reduce the overall risk of being diagnosed with prostate cancer while on therapy — finasteride in the Prostate Cancer Prevention Trial and dutasteride in the REDUCE trial.[7][8] This is a genuine, useful counselling point for a patient with BPH who is also concerned about his prostate cancer risk and is deciding whether to start a 5-alpha-reductase inhibitor — the risk-reduction effect is a real secondary benefit of a drug already being considered for symptom control, not a reason to start a 5-ARI in a man who has no BPH indication for one.
Depression, self-harm, suicidality, and muscle-related effects
5-alpha-reductase inhibitor therapy has been associated with an increased risk of self-harm and depression, most pronounced in the first 18 months after starting treatment, though without an increased risk of completed suicide, in a large cohort of men 66 years of age and older.[9] Separately, Health Canada's most recent safety review (completed January 2023) found a possible link between finasteride and suicidal ideation and self-injury; screen for depression, suicidal ideation, self-harm, and related risk factors before starting a 5-alpha-reductase inhibitor and periodically during treatment, and counsel patients that these effects have been reported to persist in some cases after stopping the drug.[10] Health Canada has also concluded that a risk of serious muscle-related adverse effects (myopathy, rhabdomyolysis) with finasteride cannot be ruled out — advise patients to promptly report unexplained muscle pain, weakness, or dark urine.[11]
Monitoring & Follow-Up
- Watchful waiting: periodic reassessment of symptoms/bother (IPSS) and screening for new red flags at intervals guided by clinical judgment.
- Alpha-blocker: reassess response and tolerability within a few weeks, since maximal response is seen within weeks; check blood pressure and orthostatic symptoms, especially with nonselective agents.
- 5-alpha-reductase inhibitor: reassess symptom response at 6 months, since full effect can take up to 6-12 months; re-baseline PSA at 6 months (see Special Populations); screen for depression/self-harm and sexual dysfunction at follow-up.
- Combination therapy: after 6-9 months of successful combination therapy, offer the option of discontinuing the alpha-blocker component; restart it if symptoms recur.[1]
- Antimuscarinic/beta-3 agonist: assess specifically for urinary retention during the first month of treatment, when the risk is highest; reassess PVR if there is any concern; monitor for typical anticholinergic effects, and monitor blood pressure with mirabegron.
- Desmopressin: check serum sodium at baseline before starting, then again at 4-8 days and at 30 days after initiation (and after any dose increase); monitor more frequently in men 65 and older or those taking other medications associated with hyponatremia; stop if serum sodium falls below the normal range.[1]
- Post-surgical: follow up 4-6 weeks after catheter removal with symptom reassessment (IPSS) and, if indicated, uroflowmetry/PVR; screen for adverse effects of the procedure.
- General: continue effective drug therapy indefinitely, since symptoms recur when medication is stopped; reassess for red flags — new hematuria, a rising or unexpected PSA, a DRE change, recurrent UTI, or deteriorating renal function — at every visit regardless of how well symptoms are controlled.
Common Errors to Avoid
- Starting presumptive BPH treatment without a DRE and appropriate red-flag screening.
- Abandoning a 5-alpha-reductase inhibitor as "not working" before 6 months — its effect on symptoms and prostate volume develops slowly.
- Adding a PDE5 inhibitor to an alpha-blocker without first stabilizing the patient on the alpha-blocker — additive hypotension risk.
- Prescribing tadalafil to a patient taking any nitrate or a guanylate cyclase stimulator.
- Misinterpreting a PSA result in a man on a 5-alpha-reductase inhibitor without accounting for the drug's suppressive effect — this risks missing prostate cancer.
- Starting an antimuscarinic or beta-3 agonist in a man with a significantly elevated post-void residual or a history of spontaneous acute urinary retention without caution.
- Not asking about alpha-blocker use before a planned cataract surgery, or failing to ensure it is disclosed to the ophthalmologist.
- Recommending decongestants or other alpha-adrenergic agonists to a man with BPH-related LUTS — these can worsen bladder outlet obstruction and blunt the benefit of alpha-blocker therapy.
- Treating acute urinary retention as something to try medication for, instead of the emergency it is — immediate catheterization comes first.
- Recommending saw palmetto or other phytotherapeutic agents as an evidence-based alternative to standard pharmacotherapy — current guidance does not recommend these agents, since trial evidence has not shown a benefit over placebo.[1]
- Forgetting to screen for depression, self-harm, and suicidal ideation before and during 5-alpha-reductase inhibitor therapy.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. BPH does not occur in pediatric patients, so no pediatric dosing applies to any drug below. Select any drug name to open its complete Pharmasist Drug Database page.
Alpha1-adrenergic receptor antagonists (alpha-blockers)
Reduce the dynamic component of bladder outlet obstruction by relaxing smooth muscle in the bladder neck, prostate, and urethra. Uroselectivity (targeting alpha1A/alpha1D receptors in the urinary tract over alpha1B receptors in vascular smooth muscle) determines the balance between ejaculatory and blood-pressure-related adverse effects; all agents have equal clinical effectiveness for symptom relief. Maximal response is typically seen within weeks.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Tamsulosin | Standard dose: 0.4 mg PO once daily, same time each day, with or without food If tolerated but response insufficient: May increase to 0.8 mg PO once daily | Dizziness, retrograde ejaculation | May potentiate other antihypertensives and PDE5 inhibitors; concurrent strong CYP3A4 or CYP2D6 inhibitors may raise levels | Highly uroselective. The alpha-blocker most consistently linked to intraoperative floppy iris syndrome (IFIS) — ask about use before any planned cataract surgery, and ensure it is disclosed to the ophthalmologist. |
| Alfuzosin | Standard dose: 10 mg PO once daily after the same meal each day | Dizziness, headache, fatigue, upper respiratory tract infection | May potentiate other antihypertensives and PDE5 inhibitors; avoid with potent CYP3A4 inhibitors | Moderately uroselective. No dose titration required. Avoid in significant hepatic impairment. Has a role in acute urinary retention (see Drug Table for choose-initial-treatment). |
| Silodosin | Standard dose: 8 mg PO once daily after the same meal each day Moderate renal impairment (ClCr 30-50 mL/min): 4 mg PO once daily | Diarrhea, dizziness, headache, nasal congestion, markedly decreased ejaculate volume | Increased silodosin levels with P-glycoprotein, CYP3A4, or UGT2B7 inhibitors; may potentiate other antihypertensives and PDE5 inhibitors | Highly alpha1A-selective. Contraindicated with severe renal impairment (ClCr under 30 mL/min) or significant hepatic disease. |
| Doxazosin | Starting dose: 1 mg PO once daily at bedtime Titration: Increase at intervals guided by response/tolerance up to 8 mg once daily | Orthostatic hypotension, dizziness, headache, asthenia, nasal congestion, syncope | May cause significant hypotension with other alpha-blockers, antihypertensives, or PDE5 inhibitors | Nonuroselective. Requires blood pressure monitoring and titration; take at bedtime to reduce first-dose hypotension risk. |
| Terazosin | Starting dose: 1 mg PO once daily at bedtime Titration: Increase at intervals guided by response/tolerance up to 10 mg once daily | Orthostatic hypotension, dizziness, headache, asthenia, nasal congestion, syncope | May cause significant hypotension with other alpha-blockers, antihypertensives, or PDE5 inhibitors | Nonuroselective. Requires blood pressure monitoring and titration; take at bedtime to reduce first-dose hypotension risk. |
5-alpha-reductase inhibitors
Block conversion of testosterone to dihydrotestosterone, reducing prostate volume over months and addressing the static component of obstruction. Best evidence for benefit is in men with a prostate volume over 30 cc and/or PSA over 1.5 ng/mL. Suppress serum PSA — see Special Populations for interpretation.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Finasteride | Standard dose: 5 mg PO once daily | Sexual dysfunction (decreased libido, erectile dysfunction, ejaculation disorders); rare serious muscle-related effects | No clinically significant drug interactions | Type II 5-alpha-reductase inhibitor. Early clinical response within 6 months; full effect may take up to 12 months. Pregnant partners, or those planning conception, should not handle crushed or broken tablets. |
| Dutasteride | Standard dose: 0.5 mg PO once daily | Sexual dysfunction (decreased libido, erectile dysfunction, ejaculation disorders) | Combination with strong CYP3A4 inhibitors may increase dutasteride levels | Inhibits both type I and type II isoenzymes. Same onset-of-effect and pregnancy-exposure precautions as finasteride. Use caution in significant liver disease. |
| Dutasteride / tamsulosin | Standard dose: 1 capsule (dutasteride 0.5 mg / tamsulosin 0.4 mg) PO once daily, about 30 minutes after the same meal each day | Combined adverse-effect profile of both individual components | Combined drug-interaction profile of both individual components | Fixed-dose combination for men already confirmed appropriate for combination therapy (bothersome LUTS with demonstrable prostatic enlargement). |
Phosphodiesterase type 5 inhibitor
Relaxes smooth muscle in and around the prostate; the only PDE5 inhibitor approved for daily LUTS management.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Tadalafil | Standard dose: 5 mg PO once daily | Back pain, dizziness, dyspepsia, flushing, headache; rare permanent vision or hearing loss | Contraindicated with nitrates and guanylate cyclase stimulators (risk of life-threatening hypotension); may cause hypotension if combined with an alpha-blocker | Not recommended in severe renal or hepatic impairment. Stabilize the patient on an alpha-blocker before adding tadalafil. Advise patients to stop the drug and seek urgent care for any sudden change in vision or hearing. |
Antimuscarinics and beta-3 agonist
For bothersome storage symptoms, alone or added to an alpha-blocker, in men with mixed or storage-predominant LUTS. Use with caution, or avoid, when PVR exceeds 200-300 mL or there is a history of spontaneous acute urinary retention — the retention risk is highest in the first month of treatment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Mirabegron | Starting dose: 25 mg PO once daily If needed: May increase to 50 mg PO once daily | Hypertension, headache, urinary tract infection, tachycardia | Moderate CYP2D6 inhibitor — may raise levels of drugs metabolized by that pathway (e.g., some beta-blockers) | Beta-3 agonist; an option when anticholinergic adverse effects are a concern. Monitor blood pressure. |
| Solifenacin | Starting dose: 5 mg PO once daily If needed: May increase to 10 mg PO once daily | Dry mouth, constipation, blurred vision | Additive anticholinergic burden with other anticholinergic drugs; caution with strong CYP3A4 inhibitors | Antimuscarinic. Caution with renal/hepatic impairment at the higher dose given QT-prolongation potential. |
| Tolterodine | Immediate-release: 1-2 mg PO twice daily Extended-release: 2-4 mg PO once daily | Dry mouth, constipation, blurred vision | Additive anticholinergic burden with other anticholinergic drugs; caution with strong CYP3A4/CYP2D6 inhibitors | Antimuscarinic. |
| Fesoterodine | Starting dose: 4 mg PO once daily If needed: May increase to 8 mg PO once daily | Dry mouth, constipation, blurred vision | Additive anticholinergic burden with other anticholinergic drugs; caution with strong CYP3A4 inhibitors | Antimuscarinic. |
| Oxybutynin | Immediate-release: 5 mg PO 2-3 times daily Extended-release: 5-30 mg PO once daily, titrated | Dry mouth, constipation, blurred vision; more central nervous system effects (confusion) than newer antimuscarinics | Additive anticholinergic burden with other anticholinergic drugs | Antimuscarinic. Prefer a newer agent with lower CNS penetration in frail or cognitively vulnerable older men. |
Antidiuretic hormone analogue
For bothersome nocturia specifically due to nocturnal polyuria, confirmed on a voiding diary, that has not responded to conservative measures or other BPH therapy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Desmopressin | Starting dose: Lowest effective dose PO once daily at bedtime Titration: Titrate to response and tolerability under sodium monitoring | Hyponatremia, headache, nausea, abdominal pain | Carbamazepine may potentiate the antidiuretic effect; demeclocycline, lithium, and norepinephrine may decrease it | Check baseline serum sodium before starting; recheck at 4-8 days and at 30 days after initiation (and after any dose increase). Monitor more frequently in men 65 and older. Contraindicated in type 2B or platelet-type (pseudo) von Willebrand disease; use great caution with impaired water excretion or sodium-losing states. |
Phytotherapeutic agents (not recommended)
Serenoa repens (saw palmetto), Pygeum africanum (African plum bark), and Urtica dioica (stinging nettle) are the most commonly used plant-based preparations for LUTS. Formulation and pharmacokinetics of the active ingredients are inconsistent across products, and current guidance does not recommend phytotherapeutic agents as standard treatment for LUTS/BPH, since trial evidence has not shown a benefit over placebo.[1]
Evidence note: drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against the current CUA guideline and the 2023 AUA guideline amendment.[1][2]
References
- UPDATE - 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) — Canadian Urological Association Journal (Elterman D, Aube-Peterkin M, Evans H, Elmansy H, Meskawi M, Zorn KC, Bhojani N). Can Urol Assoc J 2022;16(8):245-256
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 — Journal of Urology, American Urological Association (Sandhu JS, Bixler BR, Dahm P, et al.). J Urol 2024;211(1):11-19
- EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms — European Association of Urology Guidelines Office (Gravas S, Cornu JN, et al., chairs). EAU Guidelines, 2026 edition
- The American Urological Association symptom index for benign prostatic hyperplasia — Journal of Urology (Barry MJ, Fowler FJ Jr, O'Leary MP, et al., Measurement Committee of the American Urological Association). J Urol 1992;148(5):1549-1557
- Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study — Journal of Urology (Lusty A, Siemens DR, Tohidi M, et al.). J Urol 2021;205(5):1430-1437
- Intraoperative floppy iris syndrome associated with tamsulosin — Journal of Cataract and Refractive Surgery (Chang DF, Campbell JR). J Cataract Refract Surg 2005;31(4):664-673
- The influence of finasteride on the development of prostate cancer — New England Journal of Medicine (Thompson IM, Goodman PJ, Tangen CM, et al., Prostate Cancer Prevention Trial). N Engl J Med 2003;349(3):215-224
- Effect of dutasteride on the risk of prostate cancer — New England Journal of Medicine (Andriole GL, Bostwick DG, Brawley OW, et al., REDUCE Study Group). N Engl J Med 2010;362(13):1192-1202
- Association of suicidality and depression with 5alpha-reductase inhibitors — JAMA Internal Medicine (Welk B, McArthur E, Ordon M, et al.). JAMA Intern Med 2017;177(5):683-691
- Summary Safety Review - Finasteride - Assessing the Potential Risks of Suicide, Suicidal Thoughts (Suicidal Ideation) and Self-injury — Health Canada, MedEffect Canada. Health Canada Summary Safety Review, completed January 2023
- Summary Safety Review - Finasteride - Assessing the Potential Risk of Serious Muscle-Related Side Effects — Health Canada, MedEffect Canada. Health Canada Summary Safety Review, June 22, 2017
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.